Canadian Researcher Guide · 2026
Ipamorelin in Canada: Benefits, Research & Where to Buy
Ipamorelin is one of the most studied growth hormone-releasing peptides available today, and for researchers in Canada it’s become a benchmark compound in the GH secretagogue category. What sets it apart from older peptides in its class isn’t just potency — it’s selectivity. Ipamorelin triggers growth hormone release without pulling cortisol, prolactin, or ACTH along for the ride, which changes what you can actually study and measure when you use it.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide — five amino acids long — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was developed by Novo Nordisk in the late 1990s and first described in the scientific literature in 1998 by Raun et al. in the European Journal of Endocrinology, where it was named “the first selective growth hormone secretagogue.”
It belongs to the GHRP (Growth Hormone-Releasing Peptide) class and works by acting as a selective agonist at the GHS-R1a receptor — the same ghrelin receptor that older GHRPs like GHRP-6 and GHRP-2 also target. The difference is that Ipamorelin binds this receptor with much higher selectivity, meaning it does the one thing you want (trigger GH release from the pituitary) without activating the secondary hormone pathways that make older GHRPs harder to work with.
The D-amino acids at positions 3 and 4 of the peptide chain are a deliberate structural choice — they make the molecule resistant to enzymatic breakdown, giving it a longer functional half-life than endogenous GHRH. In human pharmacokinetic studies, Ipamorelin produces a single, clean GH pulse peaking around 40 minutes post-injection with a terminal half-life of approximately 2 hours.
How Ipamorelin Works: The Mechanism in Detail
When Ipamorelin binds to GHS-R1a receptors on somatotroph cells in the anterior pituitary, it triggers a cascade: the receptor activates Gq/11 proteins, which activate phospholipase C, which generates IP3 and DAG, which releases intracellular calcium. That calcium spike is what causes the pituitary to release growth hormone in a pulse.
The selectivity is what makes the mechanism notable. GHRP-6, for example, also activates receptors that stimulate cortisol and prolactin release — an effect that complicates both research protocols and safety profiles. Ipamorelin’s receptor binding profile shows minimal cross-reactivity with those pathways. In comparative studies, Ipamorelin produced significant GH release at all tested doses without any meaningful elevation of ACTH, cortisol, or prolactin.
After GH is released, IGF-1 is produced in the liver in response. IGF-1 is the downstream mediator of most of GH’s tissue-level effects: muscle protein synthesis, fat breakdown (lipolysis), collagen production, bone remodeling, and cellular repair. Ipamorelin also preserves the body’s natural somatostatin feedback — meaning GH levels remain within a physiologically controlled range rather than running unchecked as they would with exogenous HGH.
What the Research Shows
Ipamorelin has accumulated over two decades of preclinical data and has passed through Phase II human clinical trials, giving it a deeper evidence base than many peptides in Canada. Here’s what the studies actually found, broken down by area.
Muscle Mass and Body Composition
A 9-week study published in Biochemical and Biophysical Research Communications (Lall et al., 2001) tested Ipamorelin head-to-head against synthetic HGH in both GH-deficient and normal mice. GH-deficient mice treated with Ipamorelin showed a 15.3% increase in body weight over the study period. Critically, unlike the HGH group — which showed increased liver weight, a marker of organomegaly — the Ipamorelin group showed no changes in relative organ weight. This suggests the anabolic effects of Ipamorelin are muscle-directed rather than driving unwanted tissue growth elsewhere.
The mechanism for muscle growth runs through IGF-1-mediated satellite cell activation and increased protein synthesis. GH released in response to Ipamorelin signals the liver to produce IGF-1, which then binds receptors on muscle fibers, promoting hypertrophy and accelerating repair after mechanical stress.
Bone Density and Longitudinal Bone Growth
A study by Johansen et al. (1999) in Growth Hormone & IGF Research tested three doses of Ipamorelin (18, 90, and 450 mcg/day) in adult female rats over 15 days. Bone growth rate increased dose-dependently from 42 microns/day in the control group to 52 microns/day in the highest-dose group — a statistically significant result (p<0.0001).
A separate study by Svensson et al. (2000) in the Journal of Endocrinology compared Ipamorelin and GHRP-6 in adult female rats and found both compounds increased total bone mineral content as measured by DEXA scan. Tibial bone mineral density also increased. A further study by Andersen et al. demonstrated that Ipamorelin completely reversed glucocorticoid-induced bone loss in rats — a particularly relevant finding for researchers studying steroid-related bone resorption, since glucocorticoids are one of the most common causes of secondary osteoporosis in clinical settings.
Fat Metabolism and Body Composition
GH is one of the body’s primary lipolytic hormones — it signals fat cells to break down stored triglycerides and release free fatty acids for energy, a process particularly active in visceral adipose tissue. By triggering GH release, Ipamorelin activates this pathway without the insulin resistance risk that comes with direct HGH at supraphysiological doses.
In the Lall et al. 9-week mouse study, non-GH-deficient mice treated with Ipamorelin showed a 16.9% increase in body weight — but importantly, this was lean mass gain, with no organ enlargement. The pattern of weight gain also differed: Ipamorelin produced most of its weight effect in the first 1–2 weeks, whereas HGH drove consistent weight gain across the full 9 weeks, suggesting the two compounds work through meaningfully different kinetics.
Sleep Architecture
Most of the body’s natural GH secretion happens during slow-wave (deep) sleep. Because Ipamorelin stimulates GH release through the same pituitary pathway, and because that GH pulse is timed to the evening injection, researchers have found that nocturnal Ipamorelin dosing aligns GH release with the body’s existing sleep-linked secretion rhythm rather than disrupting it. This is the opposite of what happens with morning HGH injections, which inject GH out of phase with the natural circadian pattern.
Multiple clinical providers using Ipamorelin in patients with low GH have reported improvements in sleep onset and slow-wave sleep depth, consistent with GHRH research showing that GH secretagogues increase slow-wave sleep in both young and older adults.
Post-Surgical GI Recovery
Ipamorelin reached Phase II human clinical trials for a GI application: post-operative ileus (POI), the delayed return of gut motility after abdominal surgery. A multicenter, double-blind, placebo-controlled trial (Beck et al., 2014, International Journal of Colorectal Disease) enrolled 117 patients undergoing bowel resection. Patients received 0.03 mg/kg Ipamorelin or placebo twice daily. Median time to first tolerated meal was 25.3 hours in the Ipamorelin group vs. 32.6 hours in placebo — a meaningful difference, though the study didn’t reach statistical significance due to its small size and broad patient population. Notably, adverse events were actually lower in the Ipamorelin group (87.5%) than in the placebo group (94.8%), confirming the safety profile.
Glucocorticoid-Induced GH Suppression
Glucocorticoids (like prednisone and methylprednisolone) suppress GH secretion as a side effect, which contributes to muscle wasting and bone loss in patients on long-term steroid therapy. A rat study by Malmlöf et al. (1999) demonstrated that Ipamorelin completely negated this suppression — animals on methylprednisolone showed normal GH responses when given Ipamorelin. This is a specific and clinically relevant finding that distinguishes Ipamorelin from GHRH-based compounds, since the mechanism runs through the ghrelin receptor rather than the GHRH receptor that steroids suppress.
Ipamorelin vs. Older GHRPs: Why Selectivity Matters
The GHRP class includes GHRP-2, GHRP-6, and Hexarelin, all of which were developed before Ipamorelin. Each one stimulates GH release, but none of them match Ipamorelin’s selectivity. Here’s how they compare:
GHRP-6 produces a strong GH pulse but also significantly elevates cortisol, prolactin, and appetite (via the ghrelin effect on the hypothalamus). For body composition research, the cortisol elevation is a confounding variable. For clinical use, the hunger stimulation is often unwanted.
GHRP-2 is more potent than GHRP-6 and raises cortisol and prolactin less, but still meaningfully. It’s cleaner than GHRP-6 but not as selective as Ipamorelin.
Hexarelin is the most potent of the older GHRPs but also the least selective — it elevates cortisol and prolactin substantially and has been shown to cause pituitary desensitization with repeated dosing.
Ipamorelin produces a GH pulse comparable to or larger than GHRP-2 while showing no meaningful effect on cortisol, prolactin, or ACTH. This makes it the preferred GHRP for long-term research protocols where hormonal side effects would compromise the data — or the subject.
The Boss Peptides Ipamorelin Lineup: Which Blend Is Right for Your Research?
Ipamorelin is most commonly used as part of a stack rather than alone, because pairing it with a GHRH-axis peptide produces a synergistic GH pulse larger than either compound alone. Each combination targets a slightly different aspect of GH physiology. Here’s a breakdown of every formulation available, with the research rationale behind each.
Ipamorelin (5mg) — Standalone
The standalone Ipamorelin (5mg) is the right choice when you need to isolate the ghrelin receptor pathway without any GHRH axis variables. Because Ipamorelin works through GHS-R1a exclusively, it lets researchers study GH secretagogue effects cleanly — no GHRH receptor activation, no somatostatin interplay from GHRH analogs. It’s also useful as a baseline when establishing a research protocol before introducing additional compounds.
Sermorelin & Ipamorelin Blend (10mg) — The Classic Dual-Pathway Stack
The Sermorelin & Ipamorelin Blend (10mg) pairs the GHRH receptor pathway (Sermorelin) with the ghrelin receptor pathway (Ipamorelin). This is the foundational GHRH + GHRP combination in GH research — the two peptides work through completely different receptors and produce a synergistic GH pulse that’s meaningfully larger than either alone.
Sermorelin contributes the GHRH signal that tells the pituitary to both produce and prepare to release GH. Ipamorelin provides the ghrelin receptor signal that triggers the actual release. Together, they replicate the two-signal mechanism the body uses naturally to regulate GH pulsatility. This is a clean, well-characterized stack with a conservative hormonal footprint — ideal for researchers new to GHRH + GHRP combinations.
Mod GRF 1-29 & Ipamorelin Blend (10mg) — Amplified Pulse with Preserved Pulsatility
The Mod GRF 1-29 & Ipamorelin Blend (10mg) is the most widely used GHRH + GHRP combination in peptide research. Mod GRF 1-29 (also called CJC-1295 without DAC) is a modified version of the first 29 amino acids of GHRH. The key word is “without DAC” — it lacks the Drug Affinity Complex that makes CJC-1295 with DAC bind to albumin and stay active for days. Mod GRF 1-29 has a half-life of around 30 minutes, which means it fires a defined GH pulse and then clears, preserving the natural pulsatile rhythm of GH release.
Compared to Sermorelin, Mod GRF 1-29 produces a somewhat stronger GH pulse due to its structural modifications that resist enzymatic degradation. The combination with Ipamorelin amplifies this further. A 4-month study cited in the Journal of Clinical Endocrinology & Metabolism found that subjects using a Mod GRF analog gained an average of 1.26 kg of lean body mass, with secondary improvements in skin thickness and insulin sensitivity.
Tesamorelin & Ipamorelin Blend (8mg) — Targeted Visceral Fat Reduction
The Tesamorelin & Ipamorelin Blend (8mg) is built around Tesamorelin’s unique clinical profile. Tesamorelin is the only GHRH analog with FDA approval — it’s used clinically under the brand name Egrifta to treat HIV-associated lipodystrophy, a condition where visceral fat accumulates excessively around the abdomen and organs. The FDA approval means Tesamorelin has more controlled human trial data behind it than any other GHRH peptide.
The REDUCE trial and related studies found that Tesamorelin produced significant reductions in visceral adipose tissue (VAT). One study found a 4.7% absolute reduction in hepatic fat among Tesamorelin-treated subjects, translating to a 37% relative reduction in liver fat — and 35% of the Tesamorelin group achieved a hepatic fat fraction below 5%, compared to just 4% in placebo. Tesamorelin also slowed liver fibrosis progression: 10.5% fibrosis progression in the Tesamorelin group vs. 37.5% in placebo.
When paired with Ipamorelin, the two compounds approach GH release from complementary angles — Tesamorelin via the GHRH receptor, Ipamorelin via the ghrelin receptor — producing a synergistic GH pulse. Research in HIV-associated lipodystrophy models found that the Tesamorelin + Ipamorelin combination produced more pronounced visceral fat reduction than Tesamorelin alone. For researchers specifically studying visceral adiposity, metabolic syndrome, or liver fat, this is the most targeted stack in the lineup.
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) — The Triple Stack
The Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) is the most comprehensive GH secretagogue combination in the Boss Peptides catalog. It combines two GHRH-axis peptides (Tesamorelin and Mod GRF 1-29) with one ghrelin receptor agonist (Ipamorelin), covering the GHRH receptor pathway from two different angles while simultaneously hitting the ghrelin receptor.
Tesamorelin and Mod GRF 1-29 are structurally distinct GHRH analogs that activate the same receptor but differ in their half-lives, degradation resistance, and clinical profiles. Research suggests their combined use produces a synergistic increase in GH levels that surpasses either alone. Adding Ipamorelin on top of this via a completely separate receptor pathway amplifies the GH pulse further still.
The research rationale for the triple stack is documented across multiple studies. A Tesamorelin study showed visceral fat reduction and liver fat improvement. Mod GRF 1-29 research showed 1.26 kg lean mass gain over 4 months. Ipamorelin adds clean GH release, improved sleep architecture, and bone protection without cortisol or prolactin elevation. Together, these three peptides cover fat metabolism, muscle preservation, bone density, sleep quality, and metabolic function simultaneously — making this the stack of choice for researchers studying comprehensive GH axis modulation.
Safety Profile: What Ipamorelin Gets Right
Ipamorelin’s safety profile is one of the most favorable in the GHRP class, supported by both preclinical data and its Phase II human trial history. In the Beck et al. (2014) bowel resection trial — 117 patients receiving twice-daily IV Ipamorelin for up to 7 days — adverse event rates were actually lower in the treatment group than in placebo. No significant toxicity was found in any organ system across the trial’s duration.
The most common side effects reported in research settings are mild and transient: injection site redness, brief headache, and occasional flushing. Because Ipamorelin doesn’t raise cortisol, you don’t get the stress-response side effects associated with GHRP-6. Because it doesn’t raise prolactin, you avoid the sexual side effects sometimes seen with older GHRPs. Because somatostatin feedback remains intact, GH levels can’t run supraphysiological the way they can with direct HGH.
Dosing: Reference Points from the Research
There are no official dosing guidelines for Ipamorelin outside the IV dosing used in the POI trial (0.03 mg/kg twice daily). In subcutaneous research and clinical optimization contexts, 100–300 mcg per injection is the most commonly referenced range. Most protocols administer Ipamorelin once daily before bed to align with the body’s natural nocturnal GH peak, though twice-daily dosing (morning and evening) is used in some protocols targeting body composition.
Ipamorelin’s half-life of approximately 2 hours means it fires a clean GH pulse and clears the system within a few hours — which is why it pairs well with GHRH peptides that prime the pituitary in advance. The synergistic GH pulse from a GHRH + Ipamorelin combination is typically injected simultaneously, 15–30 minutes before bed on an empty stomach, to maximize alignment with the natural GH rhythm. For help calculating reconstitution volumes and injection units, the Peptide Dosage Calculator handles the math for every vial size.
Regulatory Status in Canada
Ipamorelin is not approved by Health Canada for human therapeutic use. In Canada, it is sold legally as a research chemical. WADA lists it under S2 (Peptide Hormones, Growth Factors), making it banned in all sports governed by WADA.
Where to Buy Ipamorelin in Canada
For researchers looking to buy Ipamorelin in Canada, sourcing quality is the most important variable. Ipamorelin is a short pentapeptide that degrades quickly if improperly synthesized or stored — a vial with poor purity or contamination delivers neither reliable research data nor a safe product. The minimum acceptable standard from any supplier is HPLC purity of 98% or higher, mass spectrometry identity confirmation, and a certificate of analysis from an independent third-party lab.
Boss Peptides ships across Canada from a Canadian facility, with most orders arriving within 2–3 business days. For researchers looking to buy Ipamorelin in Ontario specifically, orders typically arrive next business day. COAs are published on every product page. The full Ipamorelin lineup is below:
- 1 Ipamorelin (5mg) — standalone ghrelin receptor agonist for isolating the GHRP pathway.
- 2 Sermorelin & Ipamorelin Blend (10mg) — classic dual-pathway GHRH + GHRP stack with a clean hormonal profile.
- 3 Mod GRF 1-29 & Ipamorelin Blend (10mg) — the most widely used GHRH + GHRP pairing in peptide research, with amplified GH pulse and preserved pulsatility.
- 4 Tesamorelin & Ipamorelin Blend (8mg) — best suited for research targeting visceral fat, hepatic fat, and metabolic syndrome.
- 5 Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) — triple-pathway stack covering GHRH receptor (two angles) and ghrelin receptor simultaneously.
The Bottom Line
Ipamorelin earned its reputation as the benchmark GHRP for a reason. It’s been through human clinical trials, it has 25 years of preclinical data behind it, and its selectivity profile is genuinely better than anything that came before it in the GHRP class. The lack of cortisol and prolactin elevation isn’t just a selling point — it’s what makes long-term research protocols viable and what makes the safety profile as clean as it is.
For researchers in Canada working with GH secretagogues, the choice of which Ipamorelin formulation to use depends on what you’re studying. The standalone is for isolating the ghrelin receptor. The GHRH blends amplify GH release through a second pathway. The Tesamorelin blends add clinically validated visceral fat reduction on top. And the triple stack covers the full GH axis in one injection.
Whatever your protocol, buy from a supplier that publishes third-party lab results. If you’re looking to buy Ipamorelin in Ontario or anywhere across Canada, Boss Peptides ships from a Canadian facility with COAs on every batch.